Medical management of chronic ischemic heart disease. Selecting specific drug therapies, modifying risk factors.
According to current estimates, more than 12 million people in the United States have coronary artery disease (CAD). Slightly less than half experience angina pectoris, and more than 7 million have had a myocardial infarction. In 2000, the economic cost of CAD in this country totaled $118 billion. Given the aging of the population and the improved therapy for several other disorders, a true epidemic looms on the horizon. In this article, Dr Bales examines the long-term medical treatment of patients with known ischemic heart disease, focusing on therapies proven to alter morbidity and mortality, relieve symptoms, and modify risk factors.
Section of Cardiology, Midwestern University, Chicago College of Osteopathic Medicine, Downers Grove, Illinois, USA. rlitch2@hotmail.com
Amy C
AC
Bales
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors